Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

A Diagnostic Test for Dementia With Lewy Bodies

NCT05479552 · View on ClinicalTrials.gov ↗

Study Summary

The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Interventions

  • DIAGNOSTIC_TEST Syn-One Test

Study Locations (12)

Massachusetts

  • Mass General Hospital — Boston
  • Beth Israel Deaconess Medical Center — Boston
  • Headlands Research — Plymouth

Florida

  • University of Miami — Boca Raton
  • Neurology One — Winter Park

Arizona

  • CND Life Sciences — Scottsdale

California

  • University of California San Diego — La Jolla

Colorado

  • CenExel RMCR — Englewood

Louisiana

  • Ochsner Research — New Orleans

Michigan

  • University of Michigan — Ann Arbor

Tennessee

  • Vanderbilt University Medical Center — Nashville

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-08-15
Est. Completion 2025-10-31

Sponsor

CND Life Sciences

36 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05479552

The ClinicalTrials.gov registry entry for NCT05479552 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CND Life Sciences, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with MCI-AD, Early Stage Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention — of which Syn-One Test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05479552 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Massachusetts, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05479552 about?

NCT05479552 is a clinical study titled "A Diagnostic Test for Dementia With Lewy Bodies". The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

What is the current status of trial NCT05479552?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2022-08-15. Estimated completion is 2025-10-31.

What conditions does trial NCT05479552 study?

This clinical trial studies the following conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05479552?

The interventions under investigation include: Syn-One Test (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05479552?

This trial is sponsored by CND Life Sciences, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05479552 being conducted?

This trial has 12 study locations across Arizona, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial